Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

Nirsevimab, a monoclonal antibody with an extended half-life, is designed to protect infants from respiratory syncytial virus disease after a single intramuscular dose. This placebo-controlled trial involving 1447 preterm infants at 164 sites in 23 countries assessed the effectiveness of nirsevimab...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 383; no. 5; pp. 415 - 425
Main Authors: Griffin, M. Pamela, Yuan, Yuan, Takas, Therese, Domachowske, Joseph B, Madhi, Shabir A, Manzoni, Paolo, Simões, Eric A.F, Esser, Mark T, Khan, Anis A, Dubovsky, Filip, Villafana, Tonya, DeVincenzo, John P
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 30.07.2020
Subjects:
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first